← Leaderboards
Helen McIlleron
University Of Cape Town
$2,642,748
Attributed
$3,516,175
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $671.7K · FY2011–19$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,516,175 · 2
By mechanism
R01$3,516,175 · 2
Top collaborators
- Tawanda Gumbo5 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DosePyrazinamideDrug KineticsBaseSouth AfricaPharmaceutical PreparationsDrug CombinationsRegimenTuberculosisCohortTuberculosis TreatmentAnti-Retroviral AgentsAntitubercular AgentsRifampinTuberculosis DrugsIsoniazidAbsorptionHigh RiskAdultGuidelinesHiv InfectionsAfrica South Of The SaharaDrug Toxicity12 Year Old
Grant awards (11)
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$346,986
R01 · FY2019 · AI · contact PI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,972
R01 · FY2018 · AI · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$36,396
R01 · FY2018 · HD · contact PI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,914
R01 · FY2017 · AI · contact PI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,985
R01 · FY2016 · AI · contact PI
Pharmacometric optimization of second line drugs for MDR tuberculosis treatment$349,997
R01 · FY2015 · AI · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$321,727
R01 · FY2015 · HD · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$315,026
R01 · FY2014 · HD · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$347,419
R01 · FY2013 · HD · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$410,557
R01 · FY2012 · HD · contact PI
Optimal dosing of 1st line antituberculosis and antiretroviral drugs in children$338,196
R01 · FY2011 · HD · contact PI